{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:38:54Z","timestamp":1791329934207,"version":"4.3.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Toxicol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11419-026-00766-3","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:42:25Z","timestamp":1774266145000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative analysis and method validation of mirogabalin in postmortem blood and urine using liquid chromatography\u2013tandem mass spectrometry"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5525-8941","authenticated-orcid":false,"given":"Kenta","family":"Yuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"3","key":"766_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kai K, Kitano Y (2018) Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther 365(3):573\u2013582. https:\/\/doi.org\/10.1124\/jpet.117.247551","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"766_CR2","doi-asserted-by":"publisher","first-page":"e121402","DOI":"10.5812\/aapm.121402","volume":"11","author":"EY Chen","year":"2021","unstructured":"Chen EY, Beutler SS, Kaye AD, Edinoff AN, Khademi S-H, Stoltz AE, Rueb NR, Cornett EM, Suh WJ (2021) Mirogabalin as a novel gabapentinoid for the treatment of chronic pain conditions: An analysis of current evidence. Anesth Pain Med 11(6):e121402. https:\/\/doi.org\/10.5812\/aapm.121402","journal-title":"Anesth Pain Med"},{"key":"766_CR3","doi-asserted-by":"publisher","first-page":"1491570","DOI":"10.3389\/fphar.2024.1491570","volume":"15","author":"F Yang","year":"2024","unstructured":"Yang F, Wang Y, Zhang M, Yu S (2024) Mirogabalin as a novel calcium channel \u03b12\u03b4 ligand for the treatment of neuropathic pain: a review of clinical update. Front Pharmacol 15:1491570. https:\/\/doi.org\/10.3389\/fphar.2024.1491570","journal-title":"Front Pharmacol"},{"issue":"1","key":"766_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3344\/kjp.2021.34.1.4","volume":"34","author":"J-Y Kim","year":"2021","unstructured":"Kim J-Y, Abdi S, Huh B, Kim K-H (2021) Mirogabalin: could it be the next generation gabapentin or pregabalin? Korean J Pain 34(1):4\u201318. https:\/\/doi.org\/10.3344\/kjp.2021.34.1.4","journal-title":"Korean J Pain"},{"issue":"11","key":"766_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40261-018-0692-7","volume":"38","author":"K Duchin","year":"2018","unstructured":"Duchin K, Senaldi G, Warren V, Marbury T, Lasseter K, Zahir H (2018) Open-label single-dose study to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics of mirogabalin. Clin Drug Investig 38(11):1001\u20131009. https:\/\/doi.org\/10.1007\/s40261-018-0692-7","journal-title":"Clin Drug Investig"},{"issue":"5","key":"766_CR6","doi-asserted-by":"publisher","first-page":"e00418","DOI":"10.1002\/prp2.418","volume":"6","author":"K Brown","year":"2018","unstructured":"Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, Dishy V, Zahir H (2018) Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies. Pharmacol Res Perspect 6(5):e00418. https:\/\/doi.org\/10.1002\/prp2.418","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"766_CR7","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s12325-022-02424-7","volume":"40","author":"Y Li","year":"2023","unstructured":"Li Y, Toyama K, Nakatsu T, Ishizuka H, Wu H, Cao G, Yu J, Wang Y, Liu X, Guo B, Wu J, Yu P, Hong Z, Zhang J, Wu X (2023) Safety, tolerability and pharmacokinetics of single and multiple doses of mirogabalin in healthy Chinese participants: A randomized, double-blind, placebo-controlled study. Adv Ther 40(4):1628\u20131643. https:\/\/doi.org\/10.1007\/s12325-022-02424-7","journal-title":"Adv Ther"},{"issue":"5","key":"766_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/00498254.2021.1879408","volume":"51","author":"N Yamamura","year":"2021","unstructured":"Yamamura N, Mendel-Harary J, Brown K, Uchiyama M, Urasaki Y, Takahashi M, Warren V, Vashi V (2021) Metabolism, excretion, and pharmacokinetics of [14\u00a0C]mirogabalin, a novel \u03b12\u03b4 ligand, in healthy volunteers following oral administration. Xenobiotica 51(5):549\u2013563. https:\/\/doi.org\/10.1080\/00498254.2021.1879408","journal-title":"Xenobiotica"},{"issue":"12","key":"766_CR9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","volume":"27","author":"U Bonnet","year":"2017","unstructured":"Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27(12):1185\u20131215. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.08.430","journal-title":"Eur Neuropsychopharmacol"},{"key":"766_CR10","unstructured":"Guidance for industry (2018) bioanalytical method validation. U.S. Department of Health and Human Services. FDA"},{"issue":"13","key":"766_CR11","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1021\/ac020361s","volume":"75","author":"BK Matuszewski","year":"2003","unstructured":"Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS. Anal Chem 75(13):3019\u20133030. https:\/\/doi.org\/10.1021\/ac020361s","journal-title":"Anal Chem"},{"key":"766_CR12","unstructured":"Mirogabalin besylate (Tarlige) tablets [package insert, version 9]. Daichii-Sankyo Co., Ltd, Tokyo (2025) Japan: https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00070625.pdf. [In Japanese]. Accessed 9 July 2025"},{"key":"766_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.chroma.2017.06.026","volume":"1523","author":"DV McCalley","year":"2017","unstructured":"McCalley DV (2017) Understanding and manipulating the separation in hydrophilic interaction liquid chromatography. J Chromatogr A 1523:49\u201371. https:\/\/doi.org\/10.1016\/j.chroma.2017.06.026","journal-title":"J Chromatogr A"},{"issue":"3","key":"766_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jat\/bku004","volume":"38","author":"C Priez-Barallon","year":"2014","unstructured":"Priez-Barallon C, Carlier J, Boyer B, Benslima M, Fanton L, Mazoyer C, Gaillard Y (2014) Quantification of pregabalin using hydrophilic interaction HPLC-high-resolution MS in postmortem human samples: eighteen case reports. J Anal Toxicol 38(3):143\u2013148. https:\/\/doi.org\/10.1093\/jat\/bku004","journal-title":"J Anal Toxicol"},{"key":"766_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.forsciint.2016.03.028","volume":"262","author":"CE Hamm","year":"2016","unstructured":"Hamm CE, Gary RD, McIntyre IM (2016) Gabapentin concentrations and postmortem distribution. Forensic Sci Int 262:201\u2013203. https:\/\/doi.org\/10.1016\/j.forsciint.2016.03.028","journal-title":"Forensic Sci Int"},{"issue":"11","key":"766_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","volume":"16","author":"EP Calandre","year":"2016","unstructured":"Calandre EP, Rico-Villademoros F, Slim M (2016) Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother 16(11):1263\u20131277. https:\/\/doi.org\/10.1080\/14737175.2016.1202764","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"766_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/cpdd.582","volume":"7","author":"M Jansen","year":"2018","unstructured":"Jansen M, Mendell J, Currie A, Dow J, He L, Merante D, Dishy V, Ishizuka H, Zahir H (2018) Pharmacokinetics, pharmacodynamics, safety, and tolerability of mirogabalin when coadministered with lorazepam, zolpidem, tramadol, or ethanol: Results from drug-drug interaction studies in healthy subjects. Clin Pharmacol Drug Dev 7(6):597\u2013612. https:\/\/doi.org\/10.1002\/cpdd.582","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"766_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","volume":"24","author":"M Schulz","year":"2020","unstructured":"Schulz M, Schmoldt A, Andresen-Streichert H, Iwersen-Bergmann S (2020) Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care 24(1):195. https:\/\/doi.org\/10.1186\/s13054-020-02915-5","journal-title":"Crit Care"}],"container-title":["Forensic Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-026-00766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11419-026-00766-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-026-00766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:07:22Z","timestamp":1782378442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11419-026-00766-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1007\/s11419-026-00766-3","relation":{},"ISSN":["1860-8965","1860-8973"],"issn-type":[{"value":"1860-8965","type":"print"},{"value":"1860-8973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no financial or other relationships that could lead to a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}},{"value":"The analysis of toxic substances from the cadaver was authorized by judicial authorities and supported by official documentation. This study was conducted with the approval of the Bioethics Committee of Hamamatsu University School of Medicine (approval no. 23\u2013232).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}